Abstract
Adverse reactions to bare metal stent implantation include stent thrombosis and restenosis. Although thrombosis in bare metal stents seems mainly to be affected by procedural factors, restenosis is a more complex procedure involving mechanisms of tissue repair after vessel injury occurring during implantation. This procedure includes early platelet and leukocyte invasion, followed by smooth muscle cell proliferation, as well as further inflammatory cell recruitment mediated by expression of chemokines and leukocyte activation at the site of the injury. In this report, we will focus on the role of inflammation in the development of in-stent restenosis in bare metal stents. In particular, we will describe the pathologic evidence implicating inflammatory cell involvement in the development of restenosis in animal and human models; we will analyze the molecular mechanisms linking inflammation with restenosis; and will review the association of pre-existing or procedure-induced systemic inflammation with adverse reactions at follow-up.
Keywords: Bare metal stents, restenosis, pathology, inflammation, biomarkers, CRP, interleukins, monocytes.
Current Vascular Pharmacology
Title:Inflammatory Mechanisms of Adverse Reactions to BMS
Volume: 11 Issue: 4
Author(s): Konstantinos Toutouzas, Antonios Karanasos and Christodoulos Stefanadis
Affiliation:
Keywords: Bare metal stents, restenosis, pathology, inflammation, biomarkers, CRP, interleukins, monocytes.
Abstract: Adverse reactions to bare metal stent implantation include stent thrombosis and restenosis. Although thrombosis in bare metal stents seems mainly to be affected by procedural factors, restenosis is a more complex procedure involving mechanisms of tissue repair after vessel injury occurring during implantation. This procedure includes early platelet and leukocyte invasion, followed by smooth muscle cell proliferation, as well as further inflammatory cell recruitment mediated by expression of chemokines and leukocyte activation at the site of the injury. In this report, we will focus on the role of inflammation in the development of in-stent restenosis in bare metal stents. In particular, we will describe the pathologic evidence implicating inflammatory cell involvement in the development of restenosis in animal and human models; we will analyze the molecular mechanisms linking inflammation with restenosis; and will review the association of pre-existing or procedure-induced systemic inflammation with adverse reactions at follow-up.
Export Options
About this article
Cite this article as:
Toutouzas Konstantinos, Karanasos Antonios and Stefanadis Christodoulos, Inflammatory Mechanisms of Adverse Reactions to BMS, Current Vascular Pharmacology 2013; 11 (4) . https://dx.doi.org/10.2174/1570161111311040002
DOI https://dx.doi.org/10.2174/1570161111311040002 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology Serum Bilirubin after Acute Ischemic Stroke is Associated with Stroke Severity
Current Neurovascular Research Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Long Noncoding RNAs as Diagnostic and Therapeutic Targets for Ischemic Stroke
Current Pharmaceutical Design Development of L-Lysine Amino Acid-Based Co-Crystal of Telmisartan Using Crystal Engineering Approach to Improve Solubility, Dissolution, and Micrometric Properties
Current Drug Delivery Adherence to Secondary Prophylaxis Among Patients with Acute Rheumatic Fever and Rheumatic Heart Disease
Current Cardiology Reviews Role of Innate Immune System in Inflammation and Cardiac Remodeling After Myocardial Infarction
Current Vascular Pharmacology Circulating ACE2 in Cardiovascular and Kidney Diseases
Current Medicinal Chemistry Statin Treatment and Carotid Plaque Composition: A Review of Clinical Studies
Current Vascular Pharmacology PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Induced Human Bone Marrow Stromal Cells Differentiate into Neural Cells by bFGF and Cocultured with Olfactory Ensheathing Cells
Current Stem Cell Research & Therapy Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review
Cardiovascular & Hematological Disorders-Drug Targets Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research Low-dose Tissue Plasminogen Activator is as Effective as Standard Tissue Plasminogen Activator Administration for the Treatment of Acute Ischemic Stroke
Current Neurovascular Research A Review of Current Treatment Strategies for Varicose Veins
Recent Patents on Cardiovascular Drug Discovery The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Hypertension, Nitric Oxide, Oxidants, and Dietary Plant Polyphenols
Current Pharmaceutical Biotechnology Structural Changes in Alzheimers Disease Brain Microvessels
Current Alzheimer Research The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology